The Growing Demand for Spravato® Treatment and the Increasing Complexity of Insurance Reimbursement

The Growing Demand for Spravato® Treatment and the Increasing Complexity of Insurance Reimbursement

As mental health awareness continues to expand across the United States, more providers are offering advanced treatment options for patients suffering from long-term, treatment resistant depression (TRD). One of the fastest-growing therapies in this space is Spravato (esketamine), an FDA-approved nasal spray treatment designed for adults with treatment resistant depression and certain patients experiencing severe depressive symptoms with suicidal ideation.

Unlike traditional antidepressants, Spravato works through a different neurological pathway and has provided hope for many patients who have failed multiple medication trials. Since its FDA approval, providers across psychiatry, behavioral health, and multidisciplinary practices have increasingly incorporated Spravato services into their treatment offerings. Recent updates to FDA labeling have further expanded accessibility for patients.

However, while clinical demand continues to rise, the administrative and reimbursement side of Spravato treatment has become increasingly complex for healthcare providers. Insurance carriers frequently modify their prior authorization criteria, medical necessity requirements, documentation standards, frequency limitations, and reimbursement rules for Spravato services. Coverage requirements can vary significantly not only between insurance carriers, but also between commercial plans, Medicare Advantage plans, Medicaid managed care organizations, and pharmacy versus medical benefit pathways.

Many insurance plans now require extensive documentation prior to approval, including:

  • Documentation of failed antidepressant trials
  • Psychiatric evaluations
  • Standardized depression rating scales
  • Detailed treatment plans
  • REMS-certified administration requirements
  • Monitoring documentation
  • Ongoing progress assessments
  • Prior authorization renewals and continuation requests

In addition, some payers frequently revise their policies regarding:

  • Whether Spravato is processed under medical or pharmacy benefits
  • Specialty pharmacy requirements
  • Buy-and-bill models
  • Site-of-service rules
  • Observation period documentation
  • Frequency and duration limitations
  • Continuation-of-care criteria
  • Billing code combinations and reimbursement structures

As a result, many providers are experiencing increased denials, delayed payments, administrative burdens, and prolonged appeals processes.

This is where Comprehensive Physician Consulting (CPC) helps bridge the gap between patient care and payer reimbursement.

For over 10 years, CPC has provided multispecialty medical billing, coding, credentialing, consulting, and revenue cycle management services throughout New Jersey, Philadelphia, and nationally. As a state-certified medical billing company with certified medical coders on staff, CPC understands the evolving landscape surrounding behavioral health reimbursement, including Spravato and treatment-resistant depression services.

Our team assists with practices with:

  • Insurance verification and benefit analysis
  • Prior authorization coordination
  • Medical necessity review
  • Billing and coding support
  • Claims submission
  • Denial management
  • Appeals and reconsiderations
  • Coordination between medical and pharmacy benefits
  • Documentation workflow guidance
  • Revenue cycle optimization
  • Clearinghouse and EMR workflow integration

CPC works with practices utilizing a wide range of EMR and practice management systems across multiple specialties. Our team understands that payer rules, authorization workflows, and coding guidelines are continuously changing, especially in behavioral health and specialty medication management.

With insurance carriers tightening utilization management and increasing scrutiny on medical necessity documentation, providers need experienced billing and coding partners who can help navigate these evolving processes while allowing clinicians to focus on patient care.

As the demand for advanced depression therapies continues to grow, the operational side of Spravato treatment will remain a critical component of financial success and practice sustainability. Providers offering these services must ensure that their billing, coding, documentation, and appeals workflows remain proactive, compliant, and adaptable in an ever-changing insurance environment.